



## Silence Therapeutics to Participate in US Virtual Investor Conferences in August

21 July 2020

LONDON, Silence Therapeutics plc (LON: SLN) (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel RNA therapeutics for the treatment of serious diseases, today announces that Company management will be participating in three virtual conferences, details of which can be found below:

### **William Blair Biotech Focus Conference**

Date: Thursday, August 6, 2020  
Time: 2:00 pm EDT (19:00 BST)  
Panel: *30 Years of RNA-Targeted Therapies – Where Are We Now*

### **BTIG Virtual Biotechnology Conference**

Date: Monday, August 10, 2020  
Time: 9:30 am EDT (14:30 BST)  
Webcast link: [Silence Therapeutics fireside chat](#)

### **Canaccord 40<sup>th</sup> Annual Growth Conference**

Date: Thursday, August 13, 2020  
Time: 11:30 am EDT (16:30 BST)  
Webcast link: [Silence Therapeutics presentation](#)

Live webcasts of the BTIG Virtual Biotechnology Conference and the Canaccord Growth Conference can be accessed via the Investors section of the Company’s website at [www.silence-therapeutics.com](http://www.silence-therapeutics.com). An archived replay of the webcasts will be available for 60 days on the Company's website after the conference.

---

### **For more information, please contact:**

**Silence Therapeutics plc**  
Iain Ross, Executive Chairman  
Rob Quinn, Chief Financial Officer

Tel: +44 (0)20 3457 6900

**Investec (Nominated Adviser and Broker)**  
Daniel Adams/Gary Clarence

Tel: +44 (0) 20 7597 5970



**European IR**

**Consilium Strategic Communications**

Mary-Jane Elliott/Chris Welsh/Angela Gray

[silencetherapeutics@consilium-comms.com](mailto:silencetherapeutics@consilium-comms.com)

Tel: +44 (0) 20 3709 5700

**U.S. IR**

**Westwicke**

Peter Vozzo

[peter.vozzo@westwicke.com](mailto:peter.vozzo@westwicke.com)

Tel: +1 (443) 213-0505

**About Silence Therapeutics plc**

Silence Therapeutics is developing a new generation of medicines by harnessing the body's natural mechanism of RNA interference, or RNAi, within its cells. Its proprietary technology can selectively inhibit any gene in the genome, specifically silencing the production of disease-associated proteins. Silence's proprietary RNA chemistries and delivery systems are designed to improve the stability of molecules and enhance effective delivery to target cells, providing a powerful modular technology well suited to tackle life-threatening diseases. The Company has secured high value research and collaboration agreements with AstraZeneca, Mallinckrodt Pharmaceuticals and Takeda. For more information, please visit: <https://www.silence-therapeutics.com/>